-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Our 12-month target is $44, down from $59, 21.2x our FY 27 EPS estimate. Our multiple is below TECH's one-year historical forward average of 26.1x and the three-year average of 30.7x. We lower our FY 26 EPS estimate by $0.06 to $1.92 and our FY 27 estimate by $0.09 to $2.08. Along with peers, shares have been under pressure due to concerns around NIH and U.S. academic research funding, an important end market for the company, as well as a slowly recovering biotech funding environment. Though we see some indications of improving conditions, we prefer some of TECH's larger, more diversified peers over the near term and think shares are more likely to underperform despite expected sales/EPS growth. We note multiple recent quarters of growth for the large pharma end market and China/APAC sales. Similar to recent commentary from life sciences tools and services peers, TECH sees indications of improving biotech funding, as well as licensing and M&A activity, heading into FY 27.